Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2027

Liquid biopsy is a non-invasive alternative to surgical biopsies that allows clinicians to acquire information about a tumour from a blood sample and accordingly plan treatment. It can detect changes in tumour gene expression profiles and provide a solid foundation for personalised treatment. It can help with early detection, tumour heterogeneity, and medication resistance. It also detects epidermal growth factor receptor (EGFR) gene alterations, which are found in non-small cell lung cancer patients (NSCLC).

Market Trends for Liquid Biopsy: The number of cancer patients worldwide is increasing due to sedentary lifestyles and rising cigarette intake. One of the primary reasons driving the Liquid Biopsy Market is the increased awareness among individuals about enhanced minimally invasive (MI) techniques in cancer diagnostics. Furthermore, numerous countries' governments are funding research and development (R&D) activities to boost the adoption of modern cancer treatments. These governments are also making significant investments in the healthcare sector, which is providing lucrative growth prospects for industry players.

Aside from that, major Liquid Biopsy Market participants are concentrating on product releases in order to create customised medicine globally. They're also incorporating liquid biopsy technical innovations to improve process workflow and output. This, together with the growing use of blood-based biopsy tests for early tumour identification, is driving the industry forward. Furthermore, the growing use of exosomes for clinical diagnosis in oncology, which provides high accuracy and shortens procedure times, is fueling demand for Liquid Biopsy Market

Rapid advancements in digital polymerase chain reaction (PCR) and next-generation sequencing (NGS)-based technologies are expected to propel the market forward.

Liquid Biopsy Market is a simple, quick, non-invasive, and repeatable sample procedure that can detect changes in tumour gene expression profiles and provide a solid foundation for customised cancer treatment and early detection. Furthermore, in recent years, there has been a focus on early cancer screening, tumour progression tracking, measuring therapy response and clinical prognosis, and detecting recurrent and refractory cancers. Furthermore, due to technical advancements in both practicality and turnaround time, liquid biopsy has recently attracted considerable interest as a non-invasive alternative to tissue biopsy in cancer patients.

 Key market companies are likewise concentrating on showcasing their products at major conferences. For example, during the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January 2020, GRAIL, Inc. published updated data from its liquid biopsy trial, CCGA, which failed to show a significant improvement in sensitivity over data reported at the symposium in 2019.